Acuamark Diagnostics Secures $11.3 Million Series A Funding to Advance Innovative Assays for Improved, Cost-Effective Early-Cancer Detection
Acuamark Diagnostics (“AcuamarkDx”), an early cancer detection company, today announced the closing of an $11.3 million Series A round.
The round was led by the office of Claudio Del Vecchio and the Del Vecchio Family Foundation, and it was joined by Bruker Corporation as a new investor in AcuamarkDx. Claudio Del Vecchio has joined AcuamarkDx’s Board of Directors.
AcuamarkDx is a molecular diagnostics company that develops ultra-sensitive, automatable technology, designed for both more reliable and more cost-effective early-cancer detection, ultimately to save lives on a vast scale and reduce health-inequities in cancer care globally.
Bruker Corporation (NASDAQ: BRKR), which also contributed to Series A, is a global life-science tool and diagnostics instrumentation company, with a particular interest in early cancer detection.
“We are grateful for our investors’ confidence and the sophisticated financial and technical depth they bring to our work,” says co-founder and CEO Dr. Bernard Peperstraete, “After years of innovation and development, we are pleased with the progress of our assays. We are hard at work to continue the optimization of the assay while initiating larger scale clinical collections.”
With the Series A proceeds, Acuamark Diagnostics intends to scale its sample collections and add a number of key building blocks to its organization.
“As an investor prior to this round, I closely monitored the company’s remarkable work to improve early-cancer interception and make it broadly accessible,” says investor Mr. Del Vecchio. “With successful development and at the industrial scale the technology is designed for, AcuamarkDx will be in a highly differentiated position to help benefit our society, saving lives, yet with large, systemic cost savings as a consequence. I look forward to working closely with Bernard and the Board of Directors to help make the vision a reality and move the company to the next level.”
Mr. William Gedale, Executive Chairman, comments: “We are honored to welcome a Director of the skill and character of Mr. Del Vecchio. Claudio is a proven executive and successful investor in a wide range of businesses globally. We warmly welcome him to our group of committed Board members and colleagues.”
“Mr. Del Vecchio combines a salt-of-the-earth humanity with an innate understanding of building extra-ordinary value. He adds a wealth of wisdom and public governance experience to our Board,” Dr. Peperstraete adds.
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more